| RRC ID |
31723
|
| Author |
Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T, Ikeda F, Tawara S, Goto T, Matsumoto F, Kuwahara S.
|
| Title |
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.
|
| Journal |
Antimicrob Agents Chemother
|
| Abstract |
The efficacy of FK463, a novel water-soluble lipopeptide, was evaluated in mouse models of pulmonary aspergillosis and was compared with that of amphotericin B (AMPH-B). In the pulmonary aspergillosis models induced by intranasal inoculation, FK463 exhibited good efficacy, with 50% effective doses in the range of 0. 26 to 0.51 mg/kg of body weight; these values were comparable to those of AMPH-B. In an Aspergillus target organ assay with immunosuppressed mice, under conditions of constant plasma levels of FK463, using a subcutaneously implanted osmotic pressure pump, a significant reduction in viable fungal cells was observed at plasma FK463 levels of 0.55 to 0.80 microgram/ml or higher. We conclude that FK463 is highly effective in the treatment of pulmonary aspergillosis in this animal model. These results indicate that FK463 may be a potent parenterally administered antifungal agent for pulmonary aspergillosis.
|
| Volume |
44(3)
|
| Pages |
619-21
|
| Published |
2000-3-1
|
| DOI |
10.1128/AAC.44.3.619-621.2000
|
| PMID |
10681328
|
| PMC |
PMC89736
|
| MeSH |
Amphotericin B / therapeutic use
Animals
Antifungal Agents / therapeutic use*
Aspergillosis / drug therapy*
Aspergillosis / microbiology
Aspergillus fumigatus / drug effects*
Echinocandins
Lipopeptides
Lipoproteins / therapeutic use*
Lung Diseases, Fungal / drug therapy*
Lung Diseases, Fungal / microbiology
Micafungin
Mice
Mice, Inbred ICR
Microbial Sensitivity Tests
Peptides, Cyclic / therapeutic use*
Treatment Outcome
|
| IF |
4.904
|
| Times Cited |
74
|
|
WOS Category
|
PHARMACOLOGY & PHARMACY
MICROBIOLOGY
|
| Resource |
| Pathogenic microorganisms |
IFM 40814
IFM 41209 |
